"Additionally, thyroid dysfunction and environmental ... Patients who are more likely to experience exacerbations based on ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

The myasthenia gravis trial linked low and high doses of ... next steps Immunovant has left the door open for batoclimab in thyroid eye disease. The biotech plans to make a final decision on ...

I'm Dr. John Whyte, the Chief Medical Officer of WebMD. Today, I want to talk about a serious autoimmune condition called myasthenia gravis. It comes from the Latin and Greek which means grave ...

Generalised myasthenia gravis (gMG) is a chronic disorder in which the body's immune system mistakenly targets the neuromuscular junctions—areas where nerves signal muscles to move. This ...

Myasthenia Gravis [MG] is characterized as an autoimmune ... first-generation anti-FcRn in the targeting of patients with Thyroid Eye Disease or TED. This leads to the next program I'm going ...

Wednesday, Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG ... 3 studies of batoclimab in thyroid eye disease are available.

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.